The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Open accessAbstract
BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19. METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level. RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis. CONCLUSIONS: In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
COVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Perrett, H. R., Painter, C. D., Narayanan, A., Majowicz, S. A., Kwong, E. M., McVicar, R. N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.033 · Cited by 1,136
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System
Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., & Berger, J. S. (2020) · JAMA · doi:10.1001/jama.2020.13372 · Cited by 818
INSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 625
Hanley, B., Naresh, K. N., Roufosse, C., Nicholson, A. G., Weir, J., Cooke, G. S., Thursz, M., Manousou, P., Corbett, R., Goldin, R., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30115-4 · Cited by 535
Rapkiewicz, A. V., Mai, X., Carsons, S. E., Pittaluga, S., Kleiner, D. E., Berger, J. S., Thomas, S., Adler, N. M., Charytan, D. M., Gasmi, B., et al. (2020) · eClinicalMedicine · doi:10.1016/j.eclinm.2020.100434 · Cited by 533
Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019
Jiménez, D., García-Sanchez, A., Rali, P., Muriel, A., Bikdeli, B., Ruiz-Artacho, P., Le Mao, R., Rodríguez, C., Hunt, B. J., & Monreal, M. (2021) · Chest · doi:10.1016/j.chest.2020.11.005 · Cited by 468
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P. R., Pujadas, E., Arvind, V., Bose, S., Charney, A. W., Chen, M. D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.041 · Cited by 452
Angus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
Mycroft-West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Gandhi, N. S., Guimond, S. E., Miller, G. J., Meneghetti, M. C. Z., Nader, H. B., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721319 · Cited by 361
Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study
Garibaldi, B. T., Fiksel, J., Muschelli, J., Robinson, M. L., Rouhizadeh, M., Perin, J., Schumock, G., Nagy, P., Gray, J. H., Malapati, H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-3905 · Cited by 220
Lewnard, J. A., Liu, V. X., Jackson, M. L., Schmidt, M. A., Jewell, B. L., Flores, J. P., Jentz, C., Northrup, G. R., Mahmud, A., Reingold, A. L., et al. (2020) · BMJ · doi:10.1136/bmj.m1923 · Cited by 212
Heparin resistance in COVID-19 patients in the intensive care unit
White, D., MacDonald, S., Bull, T., Hayman, M., de Monteverde-Robb, R., Sapsford, D., Lavinio, A., Varley, J., Johnston, A., Besser, M., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02145-0 · Cited by 178
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Buijsers, B., Yanginlar, C., Maciej-Hulme, M. L., de Mast, Q., & van der Vlag, J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102969 · Cited by 158
Heparin‐binding protein: a key player in the pathophysiology of organ dysfunction in sepsis
Fisher, J., & Linder, A. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12604 · Cited by 150
McGlothlin, A. E., & Viele, K. (2018) · JAMA · doi:10.1001/jama.2018.17977 · Cited by 132
Flaczyk, A., Rosovsky, R. P. G., Reed, C. T., Bankhead-Kendall, B., Bittner, E. A., & Chang, M. G. (2020) · Critical Care · doi:10.1186/s13054-020-03273-y · Cited by 95
Ionescu, F., Jaiyesimi, I. A., Petrescu, I., Lawler, P. R., Castillo, E. M., Maldonado, Y. M., Imam, Z., Narasimhan, M., Abbas, A. E., Konde, A. S., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13533 · Cited by 95
Using heparin molecules to manage COVID‐2019
Liu, J., Li, J., Arnold, K., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12353 · Cited by 79
d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019
Short, S., Gupta, S., Brenner, S. K., Hayek, S. S., Srivastava, A., Shaefi, S., Singh, H., Wu, B. G., Bagchi, A., Al-Samkari, H. T., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004917 · Cited by 70
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C. A., Carrier, M., Džavík, V., Fergusson, D. A., Fowler, R., Galanaud, J. ‐., et al. (2020) · Clinical Trials · doi:10.1177/1740774520943846 · Cited by 65
Fröhlich, G., Jeschke, E., Eichler, U., Thiele, H., Alhariri, L., Reinthaler, M., Kastrati, A., Leistner, D. M., Skurk, C., Landmesser, U., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01783-x · Cited by 59
Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
Godoy, L. C., Goligher, E. C., Lawler, P. R., Slutsky, A. S., & Zarychanski, R. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.201240 · Cited by 55
Anticoagulation in Hospitalized Patients with Covid-19
Chowdhury, J. F., Moores, L. K., & Connors, J. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmclde2028217 · Cited by 49
Anticoagulation practice patterns in COVID‐19: A global survey
Rosovsky, R. P. G., Sanfilippo, K. M., Wang, T., Rajan, S. K., Shah, S., Martin, K. A., Áinle, F. N., Huisman, M. V., Hunt, B. J., Kahn, S. R., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12414 · Cited by 46
Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19
Xue, M., Zeng, Y., Qu, H., Zhang, T., Li, N., Huang, H., Zheng, P., Hu, H., Zhou, L., Duan, Z., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00741-2020 · Cited by 25
The Clinical Course of Coronavirus Disease 2019 in a US Hospital System: A Multistate Analysis
Mody, A., Lyons, P. G., Guillamet, C. V., Michelson, A. P., Yu, S., Namwase, A. S., Sinha, P., Powderly, W. G., Woeltje, K. F., & Geng, E. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa286 · Cited by 22
Cited by
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Manley, G. T., Abrams, M., Åkerlund, C., Andelic, N., Aries, M., Bashford, T., Bell, M. J., Bodien, Y. G., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00309-x · Cited by 1,520
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 650
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., et al. (n.d.) · Bern Open Repository and Information System (University of Bern) · doi:10.17863/cam.76384 · Cited by 581
Metadata
- Authors
- The ATTACC, A.-4.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-26
- Volume
- 385
- Issue
- 9
- Pages
- 790-802
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3189793200
- Cited by
- 1,046
- References
- 32
- FWCI
- 69.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.